Author

Xuexuan Liu

Institution: Arcturus Therapeutics (United States)

Observed institution: Arcturus Therapeutics (United States)

ORCID: 0009-0004-3106-6114

Observed ORCID: 0009-0004-3106-6114

OpenAlex ID: A5108974583

A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines

2024 · Nhan Thi Ho, Steve G. Hughes, et al. · npj Vaccines · 16

Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study

2025 · Michelle L. Giles, Charissa Tabora, et al. · EClinicalMedicine · 11

Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I study

2026 · Antoinette A. Pragalos, Filippo Pacciarini, et al. · Nature Communications

Works count: 3

Citation count: 27

H-index: 2

I10-index: 2